Advisory Alpha LLC Invests $297,000 in CVS Health Corporation $CVS

Key Points

• Advisory Alpha LLC has made a new investment in CVS Health Corporation, acquiring 4,390 shares valued at approximately $297,000 during the first quarter.
• CVS Health reported earnings of $1.81 EPS for the last quarter, exceeding analysts' expectations, and had a revenue of $98.92 billion, marking an 8.4% year-over-year increase.
• The company recently announced a quarterly dividend of $0.665 per share, resulting in an annualized dividend yield of 3.6%.

Advisory Alpha LLC acquired a new position in shares of CVS Health Corporation (NYSE:CVS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,390 shares of the pharmacy operator's stock, valued at approximately $297,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CVS. Janus Henderson Group PLC increased its stake in CVS Health by 0.6% in the fourth quarter. Janus Henderson Group PLC now owns 765,186 shares of the pharmacy operator's stock valued at $34,352,000 after acquiring an additional 4,283 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in CVS Health by 34.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 340,269 shares of the pharmacy operator's stock valued at $15,275,000 after acquiring an additional 86,715 shares during the period. OMERS ADMINISTRATION Corp increased its stake in CVS Health by 18.6% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 53,458 shares of the pharmacy operator's stock valued at $2,400,000 after acquiring an additional 8,375 shares during the period. Man Group plc increased its stake in CVS Health by 230.3% in the fourth quarter. Man Group plc now owns 840,814 shares of the pharmacy operator's stock valued at $37,744,000 after acquiring an additional 586,270 shares during the period. Finally, Main Street Group LTD increased its stake in CVS Health by 27.4% in the fourth quarter. Main Street Group LTD now owns 1,322 shares of the pharmacy operator's stock valued at $59,000 after acquiring an additional 284 shares during the period. Institutional investors own 80.66% of the company's stock.

CVS Health Price Performance

Shares of CVS stock opened at $73.93 on Thursday. CVS Health Corporation has a 1 year low of $43.56 and a 1 year high of $74.53. The firm's 50 day moving average is $66.82 and its 200-day moving average is $66.14. The firm has a market capitalization of $93.76 billion, a price-to-earnings ratio of 20.65, a PEG ratio of 0.79 and a beta of 0.62. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The company had revenue of $98.92 billion for the quarter, compared to analyst estimates of $94.87 billion. During the same period in the prior year, the business earned $1.83 earnings per share. CVS Health's quarterly revenue was up 8.4% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Tuesday, July 22nd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date was Tuesday, July 22nd. CVS Health's dividend payout ratio is presently 74.30%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Bernstein Bank reduced their price target on shares of CVS Health from $78.00 to $72.00 and set a "market perform" rating on the stock in a research report on Wednesday, July 16th. Zacks Research lowered shares of CVS Health from a "strong-buy" rating to a "hold" rating in a research report on Monday. UBS Group upgraded shares of CVS Health from a "neutral" rating to a "buy" rating and boosted their price target for the company from $67.00 to $79.00 in a research report on Monday, August 18th. Sanford C. Bernstein boosted their price target on shares of CVS Health from $72.00 to $77.00 and gave the company a "market perform" rating in a research report on Friday, September 5th. Finally, Baird R W upgraded shares of CVS Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, CVS Health presently has a consensus rating of "Moderate Buy" and a consensus target price of $77.89.

Insider Buying and Selling at CVS Health

In related news, Director Anne A. Finucane sold 7,500 shares of the business's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the sale, the director directly owned 22,156 shares of the company's stock, valued at $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.22% of the stock is currently owned by company insiders.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.